Blosozumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoporosis, Postmenopausal
Conditions
Osteoporosis, Postmenopausal
Trial Timeline
Jan 1, 2015 → Mar 1, 2015
NCT ID
NCT02337387About Blosozumab
Blosozumab is a phase 1 stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is terminated. This product is registered under clinical trial identifier NCT02337387. Target conditions include Osteoporosis, Postmenopausal.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02337387 | Phase 1 | Terminated |
| NCT02109042 | Phase 1 | Completed |
Competing Products
20 competing products in Osteoporosis, Postmenopausal